KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Net Income (2016 - 2025)

CRISPR Therapeutics AG's Net Income history spans 11 years, with the latest figure at -$129.7 million for Q4 2025.

  • For Q4 2025, Net Income fell 135.43% year-over-year to -$129.7 million; the TTM value through Dec 2025 reached -$580.7 million, down 1663.08%, while the annual FY2025 figure was -$580.7 million, 1662.62% down from the prior year.
  • Net Income for Q4 2025 was -$129.7 million at CRISPR Therapeutics AG, down from -$106.4 million in the prior quarter.
  • Across five years, Net Income topped out at $759.2 million in Q2 2021 and bottomed at -$208.6 million in Q2 2025.
  • The 5-year median for Net Income is -$114.9 million (2021), against an average of -$39.5 million.
  • The largest annual shift saw Net Income skyrocketed 1053.13% in 2021 before it crashed 135.43% in 2025.
  • A 5-year view of Net Income shows it stood at -$139.5 million in 2021, then grew by 19.11% to -$112.9 million in 2022, then surged by 339.24% to $270.0 million in 2023, then skyrocketed by 35.6% to $366.1 million in 2024, then plummeted by 135.43% to -$129.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Net Income are -$129.7 million (Q4 2025), -$106.4 million (Q3 2025), and -$208.6 million (Q2 2025).